Selvigaltin Explained
| Legal Status: | Investigational |
| Synonyms: | GB1211 |
| Unii: | 94EN2E6BLW |
| Pubchem: | 122443488 |
| Kegg: | D12763 |
| Chemspiderid: | 115010772 |
| Chembl: | 5182222 |
| Iuphar Ligand: | 11202 |
| Iupac Name: | (2R,3R,4S,5R,6R)-2-(5-Bromopyridin-3-yl)sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol |
| C: | 19 |
| H: | 16 |
| Br: | 1 |
| F: | 3 |
| N: | 4 |
| O: | 4 |
| S: | 1 |
| Stdinchi: | 1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2/t14-,16+,17+,18-,19-/m1/s1 |
| Stdinchikey: | FNCLKJPMEFPXOR-QFACEVIFSA-N |
| Smiles: | C1=C(C=C(C(=C1F)F)F)C2=CN(N=N2)[C@H]3[C@H]([C@H](O[C@@H]([C@@H]3O)SC4=CC(=CN=C4)Br)CO)O |
Selvigaltin (GB1211) is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered.[1] It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis[2] and resistance to checkpoint inhibitors (a type of anti-cancer drug).[3] [4]
Notes and References
- Aslanis . Vassilios . Slack . Robert J. . MacKinnon . Alison C. . McClinton . Catherine . Tantawi . Susan . Gravelle . Lise . Nilsson . Ulf J. . Leffler . Hakon . Brooks . Ashley . Khindri . Sanjeev K. . Marshall . Richard P. . Pedersen . Anders . Schambye . Hans . Zetterberg . Fredrik . Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants . Cancer Chemotherapy and Pharmacology . March 2023 . 91 . 3 . 267–280 . 10.1007/s00280-023-04513-y . 36914828 . 10010643 . 1432-0843. free .
- News: New Agent Shows Promise in Decompensated Cirrhosis . 3 December 2023 . www.gastroendonews.com.
- Ghiringhelli . François . Doucet . Ludovic . Barre . Patricia . Pichon . Eric . Ponce Aix . Santiago . Juan-Vidal . Oscar . Carcereny . Enric . Sethi . Tariq . Lindmark . Bertil . MacKinnon . Alison . Aslanis . Vassilios . Rajiwate . Zahir . Basse . Linda . GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial. . Journal of Clinical Oncology . 1 June 2022 . 40 . 16_suppl . TPS9152 . 10.1200/JCO.2022.40.16_suppl.TPS9152. 249450443 .
- Mabbitt . Joseph . Roper . James A. . Slack . Robert John . Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1. . Journal of Clinical Oncology . 1 June 2022 . 40 . 16_suppl . 2607 . 10.1200/JCO.2022.40.16_suppl.2607.
